Astrazeneca plc AZN.US Overview
AZN AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
AZN Current Performance
-1.38%
Astrazeneca plc
0.59%
Avg of Sector
0.40%
S&P500
AZN Key Information
AZN Revenue by Segments
Browsing restrictions can be lifted for a fee.
AZN Net Income
Browsing restrictions can be lifted for a fee.
AZN Cash Flow
Browsing restrictions can be lifted for a fee.
AZN Profit Margin
Browsing restrictions can be lifted for a fee.
AZN PE Ratio River
Browsing restrictions can be lifted for a fee.
AZN Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
AZN Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
AZN Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Price of AZN
AZN FAQ
When is AZN's latest earnings report released?
The most recent financial report for Astrazeneca plc (AZN) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AZN's short-term business performance and financial health. For the latest updates on AZN's earnings releases, visit this page regularly.
Where does AZN fall in the P/E River chart?
According to historical valuation range analysis, Astrazeneca plc (AZN)'s current price-to-earnings (P/E) ratio is 28.6, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of AZN?
According to the latest financial report, Astrazeneca plc (AZN) reported an Operating Profit of 17.19B with an Operating Margin of 63.42% this period, representing a growth of 451.78% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is AZN's revenue growth?
In the latest financial report, Astrazeneca plc (AZN) announced revenue of 27.1B, with a Year-Over-Year growth rate of 113.76%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does AZN have?
As of the end of the reporting period, Astrazeneca plc (AZN) had total debt of 31.65B, with a debt ratio of 0.3. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does AZN have?
At the end of the period, Astrazeneca plc (AZN) held Total Cash and Cash Equivalents of 5.23B, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does AZN go with three margins increasing?
In the latest report, Astrazeneca plc (AZN) achieved the “three margins increasing” benchmark, with a gross margin of 91.7%%, operating margin of 63.42%%, and net margin of 10.8%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AZN's profit trajectory and future growth potential.
Is AZN's EPS continuing to grow?
According to the past four quarterly reports, Astrazeneca plc (AZN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.94. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of AZN?
Astrazeneca plc (AZN)'s Free Cash Flow (FCF) for the period is 3.29B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 54.81% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.